<DOC>
	<DOC>NCT00973427</DOC>
	<brief_summary>The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).</brief_summary>
	<brief_title>DNA Chip Based Prognosis of Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>1. A histological diagnosis of primary NSCLC stage Ia 2. Surgical removal of the tumor 3. Age between 18 and 75 years 4. Ability to understand and the willingness to sign a written informed consent document. 1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage IbIV after surgery. 2. Adjuvant treatment with chemotherapy. 3. Prior history of cancer in the past 5 years or breast cancer at any time. 4. Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>NSCLC</keyword>
</DOC>